Kinases are critical in many biological processes, and their dysregulation is often associated with diseases, particularly cancer. Many cancers exhibit overactive kinases that drive uncontrolled cell proliferation. Consequently, kinases are significant targets for cancer therapy. Inhibitors that specifically block the activity of dysregulated kinases can be effective treatments. For example, the drug Imatinib targets the BCR-ABL kinase in chronic myeloid leukemia.
